Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05205356

VIGOR: Virtual Genome Center for Infant Health

This study will provide rigorous evaluation of implementing a virtual genome center into community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minority (URM) populations and will enhance capacity for providers and health systems to utilize highly specialized genomic techniques in their communities.

The goal of this study is to achieve equitable access to state-of-the-art genomic medical care to sick newborns in community centers that predominately care for low-income and racial/ethnic minority populations through the creation of a virtual genome center (VIGOR). VIGOR will provide a venue for physician and family education, genomic expert consultation, reanalysis of unsolved sequencing data, and access to cutting edge therapeutic innovation, thereby facilitating institutionalization of genomic best practices in community settings, and not just highly specialized referral centers.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

0 day–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

USA Children's and Women's Hospital, Mobile, Alabama, United States

Loading trial locations.

About this study

Genomic medicine has rapidly advanced in the past decade enabling earlier diagnosis and personalized treatment. However, only a few highly specialized centers in the US have the resources to take advantage of these advances in patient care. This has created a large health equity gap whereby patients cared for in typical community settings, often low-income and/or representing racial/ethnic minorities, do not receive equitable medical care. Another barrier to the wider utilization of genomic medicine is the poor dissemination of knowledge among clinicians, especially in community settings. A wide gap exists in the implementation of genomic medicine from diagnosis to personalized therapies, a field experiencing huge advances but still subject to wide disparities in accessibility. This study aims to develop and test the implementation of a strategy to break down these barriers to genomic medicine. The target population is sick newborns admitted to the NICU that present with probable genetic conditions. This study proposes a novel center, VIrtual GenOme CenteR (VIGOR). VIGOR will be a center that can remotely support clinicians and families working in community NICUs.

This study will provide rigorous evaluation of implementing a virtual genome center at community clinical settings without highly specialized resources, thereby offering generalizable insights as to how best to implement genomic medicine at scale and for other age groups. This intervention has great potential to address disparities in genomic medicine among low-income and underrepresented minorities (URM) populations and will enhance capacity for providers and health systems to utilize highly specialized genomic techniques in their communities.

The goal of this study is to achieve equitable access to state-of-the-art genomic medical care to sick newborns in community centers that predominately care for low-income and racial/ethnic minority populations through the creation of a virtual genome center (VIGOR). VIGOR will provide a venue for physician and family education, genomic expert consultation, reanalysis of unsolved sequencing data, and access to cutting edge therapeutic innovation, thereby facilitating institutionalization of genomic best practices in community settings, and not just highly specialized referral centers.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newborns presenting with probable genetic conditions inpatient on the NICU. These may include (but is not limited to) those with unexplained hypotonia, seizures, metabolic disorders, disorders of sex development, interstitial lung disease, immunodeficiency or multiple congenital anomalies.
  • Babies must have at least one biologic parent available for consent and participation.
  • The criteria for inclusion are 100% phenotype based and do not include any demographic parameters.

Exclusion criteria

  • Presence of a likely nongenetic explanation for the phenotype (e.g., perinatal asphyxia explained by uterine rupture or placental pathology;
  • Clinical features pathognomonic for a recognizable chromosomal abnormality, such as trisomy 21;
  • Associations already known to have low genetic diagnostic yield, including VATER/VACTERL association and OEIS complex;
  • Infants who die before enrollment;
  • Known family history of genetic disease that is plausibly the cause of the infant's illness; - Those with a prenatal genetic diagnosis.

Treatment and study plan

Primary outcomes

  1. Implementation of VIGOR

    Time frame: 4 year

    Penetration of VIGOR measured by percentage of eligible participants who were enrolled, tested, providers received CIR and completed a disclosure session.

Secondary outcomes

  1. Implementation of VIGOR

    Time frame: 4 year

    Appropriateness of VIGOR measured at the provider level by conducting focus groups/interviews.

  2. Implementation of VIGOR

    Time frame: 4 year

    Feasibility of VIGOR measured at the provider level by conducting focus groups/interviews.

  3. Service Outcomes

    Time frame: 4 years

    Equity in penetration of VIGOR use by race/ethnicity, insurance status and primary language measured at the participant level by conducting chart reviews and surveys.

  4. Client Outcomes

    Time frame: 4 years

    Function measured at the infant/caregiver and provider level by conducting surveys, chart reviews and focus groups/interviews.

  5. Client Outcomes

    Time frame: 4 years

    Symptomatology measured at the infant/caregiver level by conducting surveys, and interviews.

  6. Client Outcomes

    Time frame: 4 years

    Satisfaction measured at the infant/caregiver and provider level by conducting surveys, chart reviews and focus groups/interviews.

Sponsors and collaborators

Lead sponsor

Boston Children's Hospital

Other

Collaborators

  • Baystate Medical Center
  • Boston Medical Center
  • DHR Health Institute for Research and Development
  • Driscoll Children's Hospital
  • Jackson Health System
  • National Human Genome Research Institute (NHGRI)
  • The Cooper Health System
  • The Hospitals of Providence East Campus
  • The Hospitals of Providence Memorial Campus
  • UMass Memorial Health
  • University of South Alabama
  • University of Texas

Registry information

Important dates

Study start
2022
Primary completion
2026
Study completion
2027
First posted
Jan 25, 2022
Registry last updated
Jul 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.